Emcure Pharmaceuticals has signed an agreement with Roche to distribute select products from the Nephrology and Transplant Medicines portfolio. Under the agreement, effective April 1, it will distribute Roche’s immunosuppressant CellCept as well as Mircera and Neorecorman, which are indicated to treat anemia caused by chronic kidney disease. Emcure on Monday said the move will help it expand its portfolio and make critical medicines available to a wider range of patients across the country.